Johnson and Johnson: Darzalex-Based Maintenance Regimens Show Clinically Meaningful Deep and Durable Responses in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
September 28, 2024
September 28, 2024
NEW BRUNSWICK, New Jersey, Sept. 28 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE: JNJ) today announced data from three stud . . .
* * *
Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE: JNJ) today announced data from three stud . . .